These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 34491754)

  • 1. Nanoparticle-Based Drug Delivery System: The Magic Bullet for the Treatment of Chronic Pulmonary Diseases.
    Pramanik S; Mohanto S; Manne R; Rajendran RR; Deepak A; Edapully SJ; Patil T; Katari O
    Mol Pharm; 2021 Oct; 18(10):3671-3718. PubMed ID: 34491754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhaled Nanoparticulate Systems: Composition, Manufacture and Aerosol Delivery.
    Mansour HM; Muralidharan P; Hayes D
    J Aerosol Med Pulm Drug Deliv; 2024 Aug; 37(4):202-218. PubMed ID: 39172256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delivering drugs to the lungs: The history of repurposing in the treatment of respiratory diseases.
    Newman SP
    Adv Drug Deliv Rev; 2018 Aug; 133():5-18. PubMed ID: 29653129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature.
    Brocklebank D; Ram F; Wright J; Barry P; Cates C; Davies L; Douglas G; Muers M; Smith D; White J
    Health Technol Assess; 2001; 5(26):1-149. PubMed ID: 11701099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advanced Therapeutic Strategies for Chronic Lung Disease Using Nanoparticle-Based Drug Delivery.
    Yhee JY; Im J; Nho RS
    J Clin Med; 2016 Sep; 5(9):. PubMed ID: 27657144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural Products-Based Inhaled Formulations for Treating Pulmonary Diseases.
    Yong J; Shu H; Zhang X; Yang K; Luo G; Yu L; Li J; Huang H
    Int J Nanomedicine; 2024; 19():1723-1748. PubMed ID: 38414528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanotechnology-based therapeutics for targeting inflammatory lung diseases.
    Loo CY; Lee WH
    Nanomedicine (Lond); 2022 May; 17(12):865-879. PubMed ID: 35315290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery.
    Willis L; Hayes D; Mansour HM
    Lung; 2012 Jun; 190(3):251-62. PubMed ID: 22274758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in nano-based drug delivery systems for the management of cytokine influx-mediated inflammation in lung diseases.
    Gulati N; Chellappan DK; MacLoughlin R; Gupta G; Singh SK; Oliver BG; Dua K; Dureja H
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Jun; 397(6):3695-3707. PubMed ID: 38078921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nano-based theranostics for chronic obstructive lung diseases: challenges and therapeutic potential.
    Vij N
    Expert Opin Drug Deliv; 2011 Sep; 8(9):1105-9. PubMed ID: 21711085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Applications and advancements of nanoparticle-based drug delivery in alleviating lung cancer and chronic obstructive pulmonary disease.
    De Rubis G; Paudel KR; Corrie L; Mehndiratta S; Patel VK; Kumbhar PS; Manjappa AS; Disouza J; Patravale V; Gupta G; Manandhar B; Rajput R; Robinson AK; Reyes RJ; Chakraborty A; Chellappan DK; Singh SK; Oliver BGG; Hansbro PM; Dua K
    Naunyn Schmiedebergs Arch Pharmacol; 2024 May; 397(5):2793-2833. PubMed ID: 37991539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Present Situation and Future Progress of Inhaled Lung Cancer Therapy: Necessity of Inhaled Formulations with Drug Delivery Functions.
    Okuda T; Okamoto H
    Chem Pharm Bull (Tokyo); 2020; 68(7):589-602. PubMed ID: 32611996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patented therapeutic drug delivery strategies for targeting pulmonary diseases.
    Thakur AK; Chellappan DK; Dua K; Mehta M; Satija S; Singh I
    Expert Opin Ther Pat; 2020 May; 30(5):375-387. PubMed ID: 32178542
    [No Abstract]   [Full Text] [Related]  

  • 14. Biocomposite-based nanostructured delivery systems for the treatment and control of inflammatory lung diseases.
    Mukherjee D; Bhatt S
    Nanomedicine (Lond); 2022 May; 17(12):845-863. PubMed ID: 35477308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rational particle design to overcome pulmonary barriers for obstructive lung diseases therapy.
    He Y; Liang Y; Han R; Lu WL; Mak JCW; Zheng Y
    J Control Release; 2019 Nov; 314():48-61. PubMed ID: 31644935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhaled Heparin: Therapeutic Efficacy and Recent Formulations.
    Yildiz-Pekoz A; Ozsoy Y
    J Aerosol Med Pulm Drug Deliv; 2017 Jun; 30(3):143-156. PubMed ID: 28418758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhaled Drug Therapy 2016: The Year in Review.
    Dhand R
    Respir Care; 2017 Jul; 62(7):978-996. PubMed ID: 28559466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhaled RNA drugs to treat lung diseases: Disease-related cells and nano-bio interactions.
    Zhang M; Lu H; Xie L; Liu X; Cun D; Yang M
    Adv Drug Deliv Rev; 2023 Dec; 203():115144. PubMed ID: 37995899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System.
    Phillips JE; Zhang X; Johnston JA
    J Vis Exp; 2017 Apr; (122):. PubMed ID: 28448027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pharmacological management of asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS).
    Albertson TE; Chenoweth JA; Pearson SJ; Murin S
    Expert Opin Pharmacother; 2020 Feb; 21(2):213-231. PubMed ID: 31955671
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.